NR4A1 and ductal breast carcinoma in situ: Adjuvant APBI or boost after BCSLow-risk group of patients is good candidate, including patients age>50 y with IDC measuring≤2cm, no ILC, no DCIS, tumor size≤30mm(pT1-2), negative margins width≥2mm, unicentric, unifocal, no EIC, no LVI, pN0, no neoadjuvant chemotherapy and any hormone receptor status.Intermediate-risk group of patients is selective candidates, including patients age>40-50 y, tumor size≤30mm(pT1-2), close surgical margins(<2mm), multifocal(limited within 2cm), no EIC, no LVI, pN1mi/pN1a, no neoadjuvant chemotherapy and any hormone receptor status.